Cargando…

Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells

BACKGROUND: Two-hydroxyglutarate (2HG) is present at low concentrations in healthy mammalian cells as both an L and D enantiomer. Both the L and D enantiomers have been implicated in regulating cellular physiology by mechanisms that are only partially characterized. In multiple human cancers, the D...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelman, Susan J., Mahieu, Nathaniel G., Cho, Kevin, Llufrio, Elizabeth M., Wencewicz, Timothy A., Patti, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665876/
https://www.ncbi.nlm.nih.gov/pubmed/26629338
http://dx.doi.org/10.1186/s40170-015-0139-z
_version_ 1782403629723942912
author Gelman, Susan J.
Mahieu, Nathaniel G.
Cho, Kevin
Llufrio, Elizabeth M.
Wencewicz, Timothy A.
Patti, Gary J.
author_facet Gelman, Susan J.
Mahieu, Nathaniel G.
Cho, Kevin
Llufrio, Elizabeth M.
Wencewicz, Timothy A.
Patti, Gary J.
author_sort Gelman, Susan J.
collection PubMed
description BACKGROUND: Two-hydroxyglutarate (2HG) is present at low concentrations in healthy mammalian cells as both an L and D enantiomer. Both the L and D enantiomers have been implicated in regulating cellular physiology by mechanisms that are only partially characterized. In multiple human cancers, the D enantiomer accumulates due to gain-of-function mutations in the enzyme isocitrate dehydrogenase (IDH) and has been hypothesized to drive malignancy through mechanisms that remain incompletely understood. While much attention has been dedicated to identifying the route of 2HG synthesis, the metabolic fate of 2HG has not been studied in detail. Yet the metabolism of 2HG may have important mechanistic consequences influencing cell function and cancer pathogenesis, such as modulating redox potential or producing unknown products with unique modes of action. RESULTS: By applying our isotope-based metabolomic platform, we unbiasedly and comprehensively screened for products of L- and D-2HG in HCT116 colorectal carcinoma cells harboring a mutation in IDH1. After incubating HCT116 cells in uniformly (13)C-labeled 2HG for 24 h, we used liquid chromatography/mass spectrometry to track the labeled carbons in small molecules. Strikingly, we did not identify any products of 2HG metabolism from the thousands of metabolomic features that we screened. Consistent with these results, we did not detect any significant changes in the labeling patterns of tricarboxylic acid cycle metabolites from wild type or IDH1 mutant cells cultured in (13)C-labeled glucose upon the addition of L, D, or racemic mixtures of 2HG. A more sensitive, targeted analysis revealed trace levels of isotopic enrichment (<1 %) in some central carbon metabolites from (13)C-labeled 2HG. However, we found that cells do not deplete 2HG from the media at levels above our detection limit over a 48 h time period. CONCLUSIONS: Taken together, we conclude that 2HG carbon is not readily transformed in the HCT116 cell line. These data indicate that the phenotypic alterations induced by 2HG are not a result of its metabolic products.
format Online
Article
Text
id pubmed-4665876
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46658762015-12-02 Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells Gelman, Susan J. Mahieu, Nathaniel G. Cho, Kevin Llufrio, Elizabeth M. Wencewicz, Timothy A. Patti, Gary J. Cancer Metab Research BACKGROUND: Two-hydroxyglutarate (2HG) is present at low concentrations in healthy mammalian cells as both an L and D enantiomer. Both the L and D enantiomers have been implicated in regulating cellular physiology by mechanisms that are only partially characterized. In multiple human cancers, the D enantiomer accumulates due to gain-of-function mutations in the enzyme isocitrate dehydrogenase (IDH) and has been hypothesized to drive malignancy through mechanisms that remain incompletely understood. While much attention has been dedicated to identifying the route of 2HG synthesis, the metabolic fate of 2HG has not been studied in detail. Yet the metabolism of 2HG may have important mechanistic consequences influencing cell function and cancer pathogenesis, such as modulating redox potential or producing unknown products with unique modes of action. RESULTS: By applying our isotope-based metabolomic platform, we unbiasedly and comprehensively screened for products of L- and D-2HG in HCT116 colorectal carcinoma cells harboring a mutation in IDH1. After incubating HCT116 cells in uniformly (13)C-labeled 2HG for 24 h, we used liquid chromatography/mass spectrometry to track the labeled carbons in small molecules. Strikingly, we did not identify any products of 2HG metabolism from the thousands of metabolomic features that we screened. Consistent with these results, we did not detect any significant changes in the labeling patterns of tricarboxylic acid cycle metabolites from wild type or IDH1 mutant cells cultured in (13)C-labeled glucose upon the addition of L, D, or racemic mixtures of 2HG. A more sensitive, targeted analysis revealed trace levels of isotopic enrichment (<1 %) in some central carbon metabolites from (13)C-labeled 2HG. However, we found that cells do not deplete 2HG from the media at levels above our detection limit over a 48 h time period. CONCLUSIONS: Taken together, we conclude that 2HG carbon is not readily transformed in the HCT116 cell line. These data indicate that the phenotypic alterations induced by 2HG are not a result of its metabolic products. BioMed Central 2015-12-01 /pmc/articles/PMC4665876/ /pubmed/26629338 http://dx.doi.org/10.1186/s40170-015-0139-z Text en © Gelman et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gelman, Susan J.
Mahieu, Nathaniel G.
Cho, Kevin
Llufrio, Elizabeth M.
Wencewicz, Timothy A.
Patti, Gary J.
Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title_full Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title_fullStr Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title_full_unstemmed Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title_short Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
title_sort evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665876/
https://www.ncbi.nlm.nih.gov/pubmed/26629338
http://dx.doi.org/10.1186/s40170-015-0139-z
work_keys_str_mv AT gelmansusanj evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells
AT mahieunathanielg evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells
AT chokevin evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells
AT llufrioelizabethm evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells
AT wencewicztimothya evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells
AT pattigaryj evidencethat2hydroxyglutarateisnotreadilymetabolizedincolorectalcarcinomacells